Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)

March 21, 2024 — Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal of predicting the risk of thrombosis by quantifying platelet FcγRIIa (pFCG test), announced the acceptance of its abstract titled Association Between Prognostic Implications of Platelet FCɣRIIA (PFCG) and Treatment Strategy for Myocardial Infarction at The American College of Cardiology (ACC) Scientific Sessions 2024 in Atlanta.

Co-Founder and Chief Science Officer David J. Schneider, MD, FACC FAHA said “I look forward to presenting these compelling results at ACC 24 to colleagues from around the world and I thank those that are participating in our ongoing clinical program.”

“We are honored to be a part of ACC 24 and to join the conversation on the latest science and innovations in this space. Individualized antiplatelet therapy is becoming a critical issue for patient care and we are excited to be leading the way,” said Pete DiBattiste, MD, FACC, FAHA, co-Founder and CEO of Prolocor.

For more information: www.prolocor.com

Find more ACC24 conference coverage here